1.Haaland B，Tan PS，de Castro G Jr，et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol，2014，9（6）：805-811.

2.Von Pawel J.Gefitinib（Iressa，ZD1839）：a novel targeted approach for the treatment of solid tumors.Bull Cancer，2004，91（5）：E70-76.

3.Mitsudomi T，Morita S，Yatabe Y，et al. Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label，randomised phase 3 trial.Lancet Oncol，2010，11（2）：121-128.

4.Zhou C，Wu YL，Chen G，et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer（OPTIMAL，CTONG-0802）：a multicentre，open-label，randomised，phase 3 study. Lancet Oncol，2011，12（8）：735-742.

5.Buter J，Giaccone G.EGFR inhibitors in lung cancer.Oncology（Williston Park），2005，19（13）：1707-11；discussion 1711-1712，1720-1723.

6.Liu HB，Wu Y，Lv TF，et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer：a systematic review and meta-analysis.PLoS One，2013，8（1）：e55128.

7.Rosell R，Carcereny E，Gervais R，et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer（EURTAC）：a multicentre，open-label，randomised phase 3 trial. Lancet Oncol，2012，13（3）：239-246.

8.Morabito A，Piccirillo MC，Falasconi F，et al. Vandetanib（ZD6474），a dual inhibitor of vascular endothelial growth factor receptor（VEGFR） and epidermal growth factor receptor（EGFR） tyrosine kinases：current status and future directions.Oncologist，2009，14（4）：378-390.

9.Mok TS，Wu YL，Thongprasert S，et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med，2009，361（10）：947-957.

10.Qi WX，Shen Z，Lin F，et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer：a systematic review and meta-analysis. Asian Pac J Cancer Prev，2012，13（10）：5177-5182.

11.Liang W，Wu X，Fang W，et al. Network meta-analysis of erlotinib，gefitinib，afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One，2014，9（2）：e85245.

12.Maemondo M，Inoue A，Kobayashi K，et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med，2010，362（25）：2380-2388.

13.Bowles DW，Weickhardt A，Jimeno A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today（Barc），2013，49（9）：523-535.

14.Dy GK，Mandrekar SJ，Nelson GD，et al. A randomized phase Ⅱ study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer：North Central Cancer Treatment Group Study N0528.J Thorac Oncol，2013，8（1）：79-88.

15.Mitchell P，Mok T，Barraclough H，et al. Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer：a systematic review. Clin Lung Cancer，2012，13（4）：239-251.

16.Kuo LC，Lin PC，Wang KF，et al. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid：a case report and literature review. Med Oncol，2011，28（1）：79-82.

17.Bria E，Milella M，Cuppone F，et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment：a metaanalysis. Ann Oncol，2011，22（10）：2277-2285.

18.Jiang H. Overview of gefitinib in non-small cell lung cancer：an Asian perspective. Jpn J Clin Oncol，2009，39（3）：137-150.